enrasentan has been researched along with s6c sarafotoxin in 1 studies
| Studies (enrasentan) | Trials (enrasentan) | Recent Studies (post-2010) (enrasentan) | Studies (s6c sarafotoxin) | Trials (s6c sarafotoxin) | Recent Studies (post-2010) (s6c sarafotoxin) |
|---|---|---|---|---|---|
| 32 | 2 | 0 | 595 | 3 | 37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elliott, JD; Guiney, S; Luengo, JI; Ohlstein, EH; Sauermelch, CF; Storer, BL; Willette, RN; Xiang, JN | 1 |
1 other study(ies) available for enrasentan and s6c sarafotoxin
| Article | Year |
|---|---|
Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
Topics: Animals; Benzofurans; Carboxylic Acids; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; Indans; Injections, Intravenous; Injections, Intraventricular; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Propionates; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Vasoconstrictor Agents; Viper Venoms | 1998 |